Mohamed Mohamed is a Hematology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
501 N Elam Ave
Greensboro, NC 274031118
Telephone
336-832-1100Provider last certified this registry record 20 Sept 2021.
Clinical trials
4 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202516 payments$17,634openpaymentsdata.cms.gov ↗
- Pharmacosmos Therapeutics Inc.Program year202510 payments$13,117openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202525 payments$12,808openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.2%Kinase inhibitor19.6%Tagrisso37%Erlotinib Hcl26%Alecensa11%Gilotrif7%Cabometyx7%Imatinib Mesylate6%Xalkori6%Part D<11 patientsThalidomide Analog6.4%Lenalidomide80%Pomalyst20%Part D<11 patients+ 2 more classes in this area
Nervous system
23.1%Phenothiazine14.1%Prochlorperazine Maleate100%Part D≥104 patientsOpioid Agonist7.3%Oxycodone-Acetaminophen57%Fentanyl25%Oxycodone Hcl18%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
14.6%Serotonin-3 Receptor Antagonist6.3%Ondansetron Hcl100%Part D≥42 patientsAntidiarrheal microorganisms3.8%Folic Acid100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”